#InvestmentAnnouncement | 🚀 We’re thrilled to announce MSM Fund’s investment in BIORCE, a Spanish TechBio innovator transforming clinical trials with AI. Together with YZR Capital, we co-led a €3.5M funding round, with support from Outsized Ventures, PATHENA, and Plug and Play Tech Center to support Biorce’s AI platform, Jarvis.
This investment will accelerate the development of Biorce’s AI-driven platform, including its proprietary AI model Jarvis, which aims to streamline clinical trial processes. With the funding, Biorce will continue to reduce costs, shorten timelines, and improve the accessibility of clinical trials, bringing new treatments to market faster.💡
Pedro Coelho, CEO and co-founder of Biorce, shares: “Clinical trials are vital for drug development but filled with inefficiencies. With our multi-modal Jarvis platform, we’re making them faster, more efficient, and accessible.” while Sofia Queiroz, Principal at MSM Fund, adds: “Biorce’s approach to integrating AI in clinical trials promises to cut both time and cost, bringing treatments closer to patients.”
Welcome, BIORCE! We’re excited to support you through this journey for real impact 🫀
Learn more ▶️ https://bit.ly/4hPBbDa